Please login to the form below
PD-L1 inhibitors
This page shows the latest PD-L1 inhibitors news and features for those working in and with pharma, biotech and healthcare.
Gilead makes a play for novel cancer drug with Tizona deal
anti-PD-1/L1 therapies and deepen responses in tumours that are sensitive to these treatments. ... Gilead, however, is looking past PD-1/L1 inhibitors to the next class of transformative treatments, with its play for Tizona just the latest in a string of
Latest news
-
Tecentriq misses the mark in advanced ovarian cancer
Tecentriq is part of a new class of immunotherapy treatments, also known as PD-1/L1 inhibitors, that have transformed the market over the last few years. ... The FDA approval for Imfinzi makes AZ’s drug the first PD-1/PD-L1 inhibitor to challenge
-
Merck KGaA, Pfizer’s Bavencio stumbles in head and neck cancer
PD-L1 inhibitor – this time stumbling in head and neck cancer. ... 1/PD-L1 inhibitors spilling across a number of cancer types and ramping up the competition.
-
AstraZeneca’s Imfinzi fails first-line bladder cancer test
PD-L1 inhibitor Imfinzi (durvalumab) – given on its own and in combination with experimental CTLA4 inhibitor tremelimumab – wasn’t able to improve overall survival in patients with advanced (stage IV) bladder ... In the trial, Imfinzi monotherapy
-
Immutep spikes on trial of its LAG-3 drug with Keytruda
The PD-1/PD-L1 checkpoint inhibitors that hit the market in 2015 have already transformed the standard of care for some cancers, but there is still a sizeable patient population ... so “the results showing an almost 50% [response] across all patients
-
Innate Pharma and AstraZeneca take monalizumab into phase 3
AZ has vested interested in Innate’s candidate because of data which shows that it can improve the effectiveness of PD-1/PD-L1 inhibitors like AZ’s own Imfinzi (durvalumab).
More from news
Approximately 1 fully matching, plus 43 partially matching documents found.
Latest Intelligence
-
Immuno-oncology in 2019: the rapid evolution continues
In addition to the PD-1 inhibitors Keytruda and Opdivo, there are four PD-L1 inhibitors: Roche’s Tecentriq, AstraZeneca’s Imfinzi, Pfizer and Merck’s Bavencio and Sanofi and ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing
-
The good, the bad and the ugly
Companies are looking to pair their PD-1/PD-L1 checkpoint inhibitors with a variety of other agents to stimulate a more robust anticancer immune response,” says Xuan.
-
European venture funding for the life science sector
is likely to accelerate interest - the sheer number of combination therapies and PD-1/PD-L1 inhibitors could result in a commoditisation of this area that could threaten returns for venture
-
Medius Deal Watch table for March 2015
170. Checkpoint Therapeutics / TG. Licence and collaboration. Human anti-PD-L1 and anti-GITR antibody preclinical programmes for haematological cancers. ... CAR-T and checkpoint inhibitors PD-1 and PD-L1. 110. Transtech / Calithera.
-
Deal Watch table for November 2014
PD-L1 and PD-1 CP inhibitors. Co-development and co-marketing alliance. 2, 850. ... FPA008 mAb inhibits (CSF1R) to be combined with nivolumab (PD-1 check-point inhibitor).
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Subscribe to our email news alerts
- Top 10 benefits of virtual advisory boards: Save Time and Resources
- NIHR launches new framework to highlight health progress outcomes
- Johns Hopkins and National Cancer Unit develop new genetic risk-scoring method for major diseases
- UKHSA secures UK-based vaccine deal for future influenza pandemics
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments
- Landscape review reveals £1.1bn of UK funding for rare diseases
No results were found
PMHub
BOLDSCIENCE
We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
